Skip to main content
Premium Trial:

Request an Annual Quote

Ag-Bio Firm NewLeaf Symbiotics Raises $17M in Series B

NEW YORK (GenomeWeb) – Agricultural biotechnology firm NewLeaf Symbiotics today said that it has raised $17 million in Series B financing.

Proceeds will be used to accelerate the St. Louis-based firm's R&D program, move production from pilot to commercial scale, and launch its first biological products, it said.

NewLeaf develops beneficial plant bacteria and uses genomics technology to discover and analyze plant/microbe interactions. It is looking to launch plant biologics based on a family of bacteria called pink-pigmented facultative methylotrophs to improve crop health and protection.

In December, the company acquired bioinformatics consulting firm Intuitive Genomics to develop bespoke solutions for analyzing and interpreting genomic data.

Otter Capital led the round with participation from existing investors RockPort Capital, Open Prairie Ventures, and Pangaea Ventures. NewLeaf previously closed a $7 million Series A financing round in January 2013.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.